Phospho-ALK (Tyr1604) Antibody detects ALK only when phosphorylated at Tyr1604 (equivalent to Tyr664 of NPM-ALK). This antibody may cross-react with other activated protein tyrosine kinases including EGFR.

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1604 of human ALK. Antibodies are purified by protein A and peptide affinity chromatography

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5).
A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8).
Phosphorylated Tyr664 of NPM-ALK (equivalent to Tyr1604 of full length ALK) is required for the interaction with PLCgamma (5). Site-directed mutagenesis of this tyrosine residue results in the loss of oncogenic activity of NPM-ALK (5).